Contineum Therapeutics, Inc.
CTNM
$9.80
-$0.59-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.75% | -3.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.15% | 6.24% | |||
| Operating Income | 1.15% | -6.24% | |||
| Income Before Tax | -0.31% | -9.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.31% | -9.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.31% | -9.78% | |||
| EBIT | 1.15% | -6.24% | |||
| EBITDA | 1.16% | -6.25% | |||
| EPS Basic | -0.21% | -9.55% | |||
| Normalized Basic EPS | -0.21% | -9.56% | |||
| EPS Diluted | -0.21% | -9.55% | |||
| Normalized Diluted EPS | -0.21% | -9.56% | |||
| Average Basic Shares Outstanding | 0.10% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||